Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
TCB-2Cat. No. 2592 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: (4-Bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine hydrobromide |
Biological Activity
High affinity 5-HT2A receptor agonist (Ki values are 0.73 and 0.75 nM for rat and human receptors respectively). Potently stimulates IP3 accumulation in NIH3T3 cells stably expressing rat 5-HT2A receptors (EC50 = 36 nM). Induces head twitches and hypothermia in mice following i.p. adminitration.Certificate of Analysis / Safety Data Sheet
References
McLean et al (2006) 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J.Med.Chem. 49 5794. PMID: 16970404.
Fox et al (2010) The serotonin 5-HT2A receptor agonist TCB-2: a behavioral and neurophysiological analysis. Psychopharmacology 212 13. PMID: 19823806.
Niebert et al (2011) Expression and function of serotonin 2A and 2B receptors in the mammalian respiratory network. PLoS One 6 e21395. PMID: 21789169.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: TCB-2, supplier, Potent, high, affinity, 5-HT2A, agonists, Serotonin, Receptors
Quick Order
Find multiple products by catalog number
5-HT Review
Written by Nicholas Barnes and John Neumaier, leading experts. Request a copy or view PDF today.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
Regulation of Vascular Reactivity by GPCRs
Written by J.J. Maguire and A.P. Davenport
'Regulation of Vascular Reactivity by G-protein-coupled Receptors' summarizes the key GPCRs regulating vascular reactivity.
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
New Products in this Area
Selective 5-HT2A antagonist
Quetiapine hemifumarate5-HT2/D2 antagonist; atypical antipsychotic
S 32212 hydrochloride5-HT2C inverse agonist; α2 antagonist
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.